PROTAC ERα Degrader-1 is a potent chemical compound designed to target the estrogen receptor alpha (ERα), a critical player in hormone-driven cancers. This molecule uniquely binds to the ligand-binding domain of ERα, facilitating its recruitment to an E3 ubiquitin ligase complex. As a bifunctional degrader, PROTAC ERα Degrader-1 connects ERα with an E3 ligase via a linker, promoting ubiquitination and subsequent proteasomal degradation of the receptor. This targeted mechanism of action allows for selective downregulation of ERα, offering a strategic advantage in disrupting ERα-mediated signaling pathways. In PROTAC design, PROTAC ERα Degrader-1 serves as a valuable tool for dissecting the role of ERα in cellular processes and exploring therapeutic avenues in ERα-positive malignancies. Its application extends to research focused on understanding the dynamics of protein degradation, evaluating the efficacy of targeted protein degradation strategies, and developing novel cancer therapeutics. This compound is indispensable for researchers aiming to elucidate the molecular intricacies of ERα regulation and degradation.
Structure of 2417369-94-7
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: Targets estrogen receptor alpha (ERα) for experimental targeted protein degradation studies.
Binding Site: Binds the ERα ligand-binding domain and cereblon thalidomide-binding pocket to support productive ternary complex formation.
Mechanism of Action: PROTAC ERα Degrader-1 is designed for use in PROTAC or targeted protein degradation experiments directed toward estrogen receptor alpha (ERα). The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.
Applications• PROTAC-Mediated ERα Degradation: This product is designed for research focused on the targeted degradation of estrogen receptor alpha (ERα). By utilizing the PROTAC mechanism, it facilitates the ubiquitination and subsequent proteasomal degradation of ERα, offering a powerful tool for dissecting estrogen receptor signaling pathways in various biological contexts.
• Targeted Protein Degradation Studies: PROTAC ERα Degrader-1 enables detailed exploration of protein degradation pathways, specifically targeting ERα. Researchers can employ this degrader to investigate the effects of selective ERα downregulation, providing insights into the role of ERα in cellular processes and disease models.
• Mechanistic Insights into PROTACs: This product serves as an exemplary model for studying the mechanistic aspects of PROTAC technology. By focusing on ERα, researchers can gain a deeper understanding of how PROTACs achieve selective protein degradation, contributing to the development of next-generation degraders in the field of targeted protein degradation.
• Functional Analysis of ERα Signaling: Utilizing PROTAC ERα Degrader-1 allows for precise manipulation of ERα levels in experimental systems. This approach enables the functional analysis of ERα-dependent signaling pathways, facilitating research into hormone-driven cancers and other ERα-related biological phenomena.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.